Header Logo

Connection

SENTHIL DAMODARAN to Humans

Back to Details
This is a "connection" page, showing publications SENTHIL DAMODARAN has written about Humans.
SENTHIL DAMODARAN
Connection Strength
0.165
Humans
  1. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. JCO Precis Oncol. 2024 Mar; 8:e2300124.
    View in: PubMed
    Score: 0.019
  2. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann Oncol. 2023 12; 34(12):1131-1140.
    View in: PubMed
    Score: 0.019
  3. Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. J Clin Oncol. 2022 05 10; 40(14):1552-1561.
    View in: PubMed
    Score: 0.016
  4. Estrogen Receptor: A Paradigm for Targeted Therapy. Cancer Res. 2021 11 01; 81(21):5396-5398.
    View in: PubMed
    Score: 0.016
  5. Clinical implications of breast cancer tumor genomic testing. Breast J. 2020 08; 26(8):1565-1571.
    View in: PubMed
    Score: 0.015
  6. Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. Hosp Pract (1995). 2012 Oct; 40(4):7-15.
    View in: PubMed
    Score: 0.009
  7. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Sci Rep. 2023 11 18; 13(1):20223.
    View in: PubMed
    Score: 0.005
  8. Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers. Cancer Res. 2023 10 02; 83(19):3264-3283.
    View in: PubMed
    Score: 0.005
  9. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469.
    View in: PubMed
    Score: 0.004
  10. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.
    View in: PubMed
    Score: 0.004
  11. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer. 2023 07 15; 129(14):2201-2213.
    View in: PubMed
    Score: 0.004
  12. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 07 01; 28(13):2878-2889.
    View in: PubMed
    Score: 0.004
  13. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022 06 01; 40(16):1816-1837.
    View in: PubMed
    Score: 0.004
  14. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. Int J Cancer. 2022 06 15; 150(12):2025-2037.
    View in: PubMed
    Score: 0.004
  15. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2021 10 01; 27(19):5365-5375.
    View in: PubMed
    Score: 0.004
  16. Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clin Cancer Res. 2021 06 01; 27(11):3243-3252.
    View in: PubMed
    Score: 0.004
  17. Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer. J Magn Reson Imaging. 2021 07; 54(1):251-260.
    View in: PubMed
    Score: 0.004
  18. Male Mammary Paget Disease: A Tale of 2 Contrasting Cases. Am J Dermatopathol. 2020 Dec; 42(12):981-985.
    View in: PubMed
    Score: 0.004
  19. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs. 2021 04; 39(2):509-515.
    View in: PubMed
    Score: 0.004
  20. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med. 2020 02; 9(3):1025-1032.
    View in: PubMed
    Score: 0.004
  21. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.
    View in: PubMed
    Score: 0.004
  22. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
    View in: PubMed
    Score: 0.003
  23. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Hum Pathol. 2019 10; 92:32-38.
    View in: PubMed
    Score: 0.003
  24. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398. Mol Cancer Ther. 2017 04; 16(4):614-624.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.